BioXcel Therapeutics, Inc. (BTAI) earnings
Quarterly results of BioXcel Therapeutics, Inc. as filed with the SEC: revenue, net income and earnings per share for each of the last 8 quarters, the latest results release and when the next one is expected.
Latest quarter: Q2 FY2026
In Q2 FY2026 (ended June 30, 2026) BioXcel Therapeutics, Inc. reported revenue of $182K (+51.7% on the same quarter a year earlier) and a net loss of $14.7M.
Diluted earnings per share were -$0.49.
Quarter by quarter
| Quarter | Revenue | vs year ago | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | $182K | +51.7% | -$14.7M | -$0.49 |
| Q1 FY2026 | $206K | +22.6% | -$12.7M | -$0.54 |
| Q4 FY2025 | $256K | -30.1% | -$12.5M | - |
| Q3 FY2025 | $98K | -54.2% | -$30.9M | -$2.18 |
| Q2 FY2025 | $120K | - | -$19.2M | -$2.45 |
| Q1 FY2025 | $168K | - | -$7.3M | -$1.50 |
| Q4 FY2024 | $366K | - | -$10.9M | - |
| Q3 FY2024 | $214K | - | -$13.7M | -$5.15 |
Results filings
- Quarterly report 10-Q
- Quarterly results 8-K
- Quarterly report 10-Q
- Annual report 10-K
- Quarterly results 8-K
What were BioXcel Therapeutics, Inc.'s latest quarterly results?
For Q2 FY2026, which ended June 30, 2026, BioXcel Therapeutics, Inc. reported revenue of $182K and a net loss of $14.7M. The figures come from its filing with the SEC.
Is BioXcel Therapeutics, Inc.'s revenue growing?
Revenue in Q2 FY2026 was $182K, up 51.7% from $120K in the same quarter a year earlier.
Get an email when BTAI reports
Follow BTAI and we email you its next results the day they are filed, with the numbers explained.